cimzia
ucb pharma sa - certolizumab pegol - crohn disease - Ónæmisbælandi lyf - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. Þegar hægt er að gefa eitt og sér í málið óþol stendur eða þegar áframhaldandi meðferð með stendur er óviðeigandi. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.
meropenem sun stungulyfs-/innrennslisstofn, lausn 1 g
sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 1 g
doktacillin stungulyfs-/innrennslisstofn, lausn
viatris aps - ampicillinum natríum - stungulyfs-/innrennslisstofn, lausn
meropenem sun stungulyfs-/innrennslisstofn, lausn 500 mg
sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 500 mg
cyltezo
boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - Ónæmisbælandi lyf - vinsamlegast skoðaðu kafla 4. 1 af samantekt á eiginleikum vöru í upplýsingaskjalinu.
nimenrix
pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - bóluefni - nimenrix er ætlað fyrir virk bólusetningar einstaklinga frá aldri 6 vikur gegn innrásar ga sjúkdóma sem orsakast af neisseria meningitidis hóp a, c, w-135, og y.
amoxicillin/clavulanic acid normon stungulyfs-/innrennslisstofn, lausn 1000/200 mg
laboratorios normon s.a. - amoxicillinum natríum; acidum clavulanicum kalíum - stungulyfs-/innrennslisstofn, lausn - 1000/200 mg
xeomin stungulyfsstofn, lausn 100 ein.
merz pharmaceuticals gmbh - botulinum toxin type a - stungulyfsstofn, lausn - 100 ein.
cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 1500 mg
fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1500 mg
cefuroxim fresenius kabi stungulyfs-/innrennslisstofn, lausn 750 mg
fresenius kabi ab - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg